Skip to main content
TipRanks
Go Ultimate75% OFF

Nektar Therapeutics (NKTR) Q3 2026 Earnings Report

1 Followers

CH:NKTR Q3 2026 EPS Results

Actual EPS
-CHF 1.37
Consensus EPS
-CHF 1.74
Beat/Miss
Beat by +CHF 0.37
One Year Ago EPS
-CHF 1.57

CH:NKTR Q3 2026 Revenue Results

Actual Revenue
CHF 7.89M
Expected Revenue
CHF 8.64M
Beat/Miss
Missed by -CHF 746.59K
YoY Revenue Growth
-20.39%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/12/2026
Time
After Close
Conference Call
Thursday, November 12, 2026
CH:NKTR Upcoming Earnings

Nektar Therapeutics's next earnings date is estimated for March 2, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

CH:NKTR Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 12, 2026|% Change Since:―|
Earnings Call Sentiment|Positive

The call was strongly focused on clinical execution and expansion, with all three atopic dermatitis phase III studies initiated, the alopecia areata study accelerated, encouraging durability and biomarker findings, multiple pipeline expansion plans, and a strong cash position with no debt. The main negatives were the sizable net loss, increased R&D spending, long timelines to pivotal data and filing, and the fact that REZPEG remains in clinical development with registration dependent on future phase III results.

Company Guidance

Nektar expects to end 2026 with more than $840 million in cash and investments, approximately $38 million in non-cash royalty revenue, R&D expense to range between $185 million and $200 million, including approximately $5 million to $10 million of non-cash depreciation and stock-based compensation expense, approximately $65 million in G&A expenses, and approximately $28 million in non-cash interest expense. The company expects initial top-line data from the ZENITH-AD studies in the summer of 2028, enrollment in the 3 AD trials around January of 2028, a goal of filing a BLA by the end of 2029, ZENITH AA data in 2029, and the ZENITH AA study to start in December; REZOLVE-AD 52-week off-treatment data are expected in the first quarter of 2027. ZENITH-AD includes 3 studies with 510 patients in each study and approximately 1,500 patients overall, while ZENITH AA will enroll approximately 850 patients and the overall ZENITH program approximately 2,400 patients; the vitiligo proof-of-concept study will include about 30 patients and generate data in late 2027 or early 2028, and the first type 1 diabetes cohort will include 18 patients, 12 on REZPEG and 6 on placebo, with six-month data expected either at the end of 2027 or the beginning of 2028.

  • REZPEG Phase III Atopic Dermatitis Program InitiatedNektar initiated all three global phase III ZENITH-AD studies in atopic dermatitis, with approximately 510 patients planned for each study and approximately 1,500 patients across the program. The program covers adults and adolescents, biologic- and JAK-inhibitor-naive and experienced patients, monotherapy, and combination use with topical corticosteroids.
  • Alopecia Areata Phase III Study Pulled ForwardThe phase III ZENITH-AA study in alopecia areata is on track to start in December 2026, earlier than originally planned for early 2027. The study is expected to enroll approximately 850 patients aged 12 and older, with data currently expected in 2029.
  • Broad REZPEG Registrational StrategyNektar expects initial top-line data from the ZENITH-AD studies in summer 2028 and is targeting submission of a biologics license application by the end of 2029. The overall ZENITH program is expected to enroll approximately 2,400 patients across atopic dermatitis and alopecia areata.
  • Regulatory Alignment Supports Topical-Corticosteroid Combination StudyFeedback from the FDA, EMA, and PMDA supported changing ZENITH AD-2 to evaluate REZPEG in combination with topical corticosteroids and to include both biologic- and JAK-inhibitor-naive and experienced patients. The company said the change is intended to strengthen the registrational package and support the broadest possible label.
  • Durable Atopic Dermatitis Responses in Phase IIbIn the phase IIb REZOLVE-AD study, monthly and quarterly maintenance dosing demonstrated sustained responses across EASI measures, clear or almost clear skin, and itch relief. Additional patients achieved response thresholds during maintenance, including complete skin clearance over time.
  • Strong Prior EASI-75 Maintenance ResultAmong patients who received 16 weeks of REZPEG at 24 micrograms per kilogram every two weeks and then three additional doses on a quarterly schedule, 83% maintained an EASI-75 response.
  • Upcoming Off-Treatment Atopic Dermatitis DataREZOLVE-AD included 125 patients who completed the maintenance period and entered off-treatment follow-up: 110 had received REZPEG and 15 had received placebo to maintain blinding. Assessments were conducted at weeks 4, 13, 26, 39, and 52, with results expected in the first quarter of 2027.
  • Durable and Deepening Alopecia Areata ResponsesPatients treated with REZPEG through week 52 demonstrated sustained hair regrowth and additional improvement during six months off treatment. Among patients treated for 52 weeks, 7% achieved SALT 10 at the end of treatment, compared with 19% six months after stopping REZPEG.
  • Planned Flexible Maintenance Dosing in Alopecia AreataIn ZENITH-AA, patients with deep responses after 52 weeks will be randomized to monthly or quarterly maintenance dosing. Patients who have not reached SALT 20 will continue every-two-week dosing because the response trajectory had not shown a plateau.
  • Positive REZPEG Biomarker FindingsIn a 100-patient REZOLVE-AD biomarker substudy, significant increases in FoxP3 and IL-2RA were observed as early as week two, along with changes across Th1, Th2, Th17, and JAK-STAT inflammatory pathways. Week-two increases in IL-10 and TGF-beta1 and reductions in TARC were significantly correlated with greater improvement in EASI scores at week 16.
  • Consistent Clinical Activity in Biomarker SubstudyREZPEG-treated patients in the biomarker substudy achieved a mean 64% reduction in EASI at week 16, consistent with the broader study population.
  • Expansion Into VitiligoNektar plans to start a proof-of-concept study of REZPEG in approximately 30 patients with active, non-segmental vitiligo in the next few months, with data expected in late 2027 or early 2028. The company cited approximately 1.9 million Americans with vitiligo and said only 15% seek treatment.
  • Additional Autoimmune Development OpportunitiesThe TrialNet-sponsored phase II study in new-onset type 1 diabetes is ongoing. The first cohort includes 18 patients, with 12 receiving REZPEG and 6 receiving placebo; six-month data are expected at the end of 2027 or the beginning of 2028. Nektar is also exploring additional indications, including asthma, and continues preclinical work on its TNFR2 program, including NKTR-0166.
  • Large Addressable Dermatology MarketsManagement cited a U.S. atopic dermatitis treatment market expected to exceed $30 billion by 2033 and an alopecia areata market forecast to reach approximately $5.2 billion by 2033. Management also said that a 10% atopic dermatitis market share could represent a potentially $3 billion to $4 billion product.
  • Evidence of Demand for Novel MechanismsManagement cited claims data showing NEMLUVIO captured at least 10% of new treatment starts approximately seven quarters after launch, while DUPIXENT's share of new-to-brand starts declined from 81% in 2024 to 65% currently. More than half of the share lost by DUPIXENT went to novel mechanisms of action. Approximately 90% of surveyed dermatologists said they would consider starting a patient on REZPEG before another biologic or a JAK inhibitor.
  • Strong Cash Position and No DebtNektar ended the third quarter with approximately $953 million in cash and investments and no debt. The company expects to end 2026 with more than $840 million in cash and investments, at or above the top end of its previously provided range of $815 million to $840 million.
  • Clinical Enrollment Progressing as PlannedManagement reported no major difference in enrollment between biologic-naive and biologic-experienced patients in the atopic dermatitis studies. The company expects enrollment in all three studies to be completed around January 2028, with top-line data in summer 2028.

CH:NKTR Earnings History

CH:NKTR earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 02, 20272026 (Q4)-2.07--1.5――
Nov 12, 20262026 (Q3)-1.74-1.37-1.5712.83% (+0.20)
Aug 13, 20262026 (Q2)-1.66-1.03-2.4858.31% (+1.45)
May 07, 20262026 (Q1)-1.33-1.53-3.0349.44% (+1.50)
Mar 12, 20262025 (Q4)-2.08-1.500.38-495.56% (-1.87)
Nov 06, 20252025 (Q3)-2.26-1.57-2.2730.74% (+0.70)
Aug 07, 20252025 (Q2)-2.55-2.48-3.1521.33% (+0.67)
May 08, 20252025 (Q1)-2.16-3.03-2.4-26.32% (-0.63)
Mar 12, 20252024 (Q4)-1.710.38-2.77113.64% (+3.15)
Nov 07, 20242024 (Q3)-2.51-2.27-3.0325.00% (+0.76)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed